Beckley Psytech

Beckley Psytech will work on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines that should be better than current neuropsychiatric treatments.

Beckley Psytech

The company has spun off from the non-profit Beckley Foundation and has Amanda Feilding as the director & chair of the scientific advisory board.

“Founded in 2019, Beckley Psytech is a for-profit company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.”

By raising more than $3 million in June 2020 and $18.6 million in December 2020, the company aims to bring new psychedelic medicines to market.

“Beckley Psytech will use the Series A funding to advance its lead programme exploring the use of synthetic 5-MeO-DMT, a unique psychedelic agent with a short duration of action, in the treatment of neuropsychiatric diseases.”

“This fundraise shows that our investors see the transformative potential of psychedelics as a new class of treatment for mental health and will enable us to accelerate our research and development programmes, as we prepare for our first clinical trial involving synthetic 5-MeO-DMT.”

Key Staff


Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account